Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Pancreatic Neoplasms 6Neoplasms 6Prostatic Neoplasms 5Ovarian Neoplasms 5Leukemia, Myeloid, Acute 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Multiple Myeloma 4Lung Neoplasms 4Leukemia 4Colorectal Neoplasms 4Recurrence 3Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Radiodermatitis 2Neoplasms by Site 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Communication 2Carcinoma, Transitional Cell 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1

Interventions

Gemcitabine 7Cisplatin 5Ramucirumab 3Platinum 3Paclitaxel 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3pembrolizumab 2Carboplatin 2rucaparib 1pegfilgrastim 1pazopanib 1eribulin 1enzalutamide 1enfortumab vedotin 1dehydroftorafur 1cabozantinib 1avelumab 1atezolizumab 1aflibercept 1Taxes 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Mitozytrex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urethral Neoplasms × Standard of Care × Clear all
NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡